Skip to search formSkip to main contentSkip to account menu

LY3009120

Known as: Pan-RAF Inhibitor LY3009120 
An orally available inhibitor of all members of the serine/threonine protein kinase Raf family, including A-Raf, B-Raf and C-Raf protein kinases… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

Phenylurea CompoundsPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
16 Quadruple vertical targeting of an oncogenic pathway as a treatment strategy to prevent drug resistance
Introduction Targeted cancer drugs elicit powerful initial responses but far less long-term benefits. The emergence of therapy… 
2017
2017
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer
Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases… 
2017
2017
Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers
Purpose: Identify and characterize novel combinations of sorafenib with anti-inflammatory painkillers to target difficult-to… 
2017
2017
A lung cancer-derived CRAF mutation to activate ERK pathway and to predict sensitivity to LY3009120 and trametinib.
e23197Background: During the Belgian FIELT II clinical study, two non-small cell lung cancers among 41 were found to harbor a… 
2016
2016
Abstract 282: Pan-RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4 and 6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, including melanoma, lung… 
2016
2016
Abstract 930: Combined inhibition of pan-RAF and VEGFR-2 mediates antitumor activity in KRAS mutant non-small cell lung cancer (NSCLC) through enhanced inhibition of tumor angiogenesis and growth
Lung cancer is the leading cause of cancer death worldwide. MAPK activation via KRAS mutation is present in up to 30% of lung… 
2015
2015
Abstract 2142: Novel oncogenic BRaf deletions functioning as BRaf homodimer and sensitive to inhibition by LY3009120, a pan Raf and Raf dimer inhibitor
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)